KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Other Accumulated Expenses (2017 - 2025)

Moderna (MRNA) has disclosed Other Accumulated Expenses for 9 consecutive years, with $73.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Accumulated Expenses changed N/A to $73.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $73.0 million, a N/A change, with the full-year FY2024 number at $221.0 million, up 71.32% from a year prior.
  • Other Accumulated Expenses was $73.0 million for Q3 2025 at Moderna, down from $192.0 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $553.0 million in Q3 2022 to a low of $42.0 million in Q2 2024.
  • A 5-year average of $206.8 million and a median of $192.0 million in 2025 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: soared 2497.4% in 2021, then crashed 48.19% in 2023.
  • Moderna's Other Accumulated Expenses stood at $225.0 million in 2021, then grew by 10.67% to $249.0 million in 2022, then plummeted by 48.19% to $129.0 million in 2023, then surged by 71.32% to $221.0 million in 2024, then crashed by 66.97% to $73.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Other Accumulated Expenses are $73.0 million (Q3 2025), $192.0 million (Q2 2025), and $221.0 million (Q4 2024).